Icosavax (Nasdaq:ICVX) - 주가, 뉴스 및 분석

ICVX 주식 개요

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. 자세한 내용

ICVX 기본 분석
눈송이 점수
가치 평가	0/6
미래 성장	0/6
과거 실적	0/6
재무 상태	6/6
배당금	0/6

위험 분석

수익이 1백만 달러 미만인 경우 ( $0 )

지난 1년 동안 주주가 희석되었습니다.

현재 수익성이 없으며 향후 3년 동안 수익을 낼 것으로 예상되지 않습니다.

최근 3개월간 주가 변동성

Icosavax, Inc. 경쟁사

Vir Biotechnology

NasdaqGS:VIR

US$1.0b

AnaptysBio

NasdaqGS:ANAB

US$768.3m

REGENXBIO

NasdaqGS:RGNX

US$473.2m

MeiraGTx Holdings

NasdaqGS:MGTX

US$499.4m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Icosavax
과거 주가
현재 주가	US$15.31
52주 최고치	US$16.11
52주 최저치	US$4.75
베타	1.28
11개월 변경	-0.78%
3개월 변경 사항	50.84%
1년 변경 사항	68.80%
33년 변화	n/a
5년 변화	n/a
IPO 이후 변화	-56.22%

최근 뉴스 및 업데이트

Recent updates

Icosavax to pursue COVID bivalent vaccine in 2023 as biotech highlights near-term milestones

Jul 28

Here's Why We're Not Too Worried About Icosavax's (NASDAQ:ICVX) Cash Burn Situation

Jun 22

Here's Why We're Not Too Worried About Icosavax's (NASDAQ:ICVX) Cash Burn Situation

Mar 24

We're Hopeful That Icosavax (NASDAQ:ICVX) Will Use Its Cash Wisely

Oct 29

주주 수익률

	ICVX	US Biotechs	US 마켓
7D	-0.6%	4.3%	1.6%
1Y	68.8%	18.8%	32.3%

수익률 대 산업: ICVX 지난 1년 동안 18 %를 반환한 US Biotechs 산업을 초과했습니다.

수익률 대 시장: ICVX 지난 1년 동안 32.4 %를 반환한 US 시장을 초과했습니다.

가격 변동성

Is ICVX's price volatile compared to industry and market?
ICVX volatility
ICVX Average Weekly Movement	15.1%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.1%

안정적인 주가: ICVX 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: ICVX 의 주간 변동성( 15% )은 지난 1년 동안 안정적이었지만 여전히 US 의 75%보다 높습니다. 주식.

회사 소개

설립	직원	CEO	웹사이트
2017	60	Adam Simpson	icosavax.com

Icosavax, Inc. 기본 사항 요약

Icosavax 의 수익과 매출은 시가총액과 어떻게 비교하나요?
ICVX 기본 통계
시가총액	US$777.79m
수익(TTM)	-US$96.71m
수익(TTM)	n/a

0.0x

P/S 비율

-8.0x

P/E 비율

ICVX 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
ICVX 손익 계산서(TTM)
수익	US$0
수익 비용	US$70.04m
총 이익	-US$70.04m
기타 비용	US$26.67m
수익	-US$96.71m

최근 보고된 수익

Sep 30, 2023

다음 수익 날짜

n/a

주당 순이익(EPS)	-1.90
총 마진	0.00%
순이익 마진	0.00%
부채/자본 비율	0%

ICVX 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

ICVX 주식 개요

위험 분석

Icosavax, Inc. 경쟁사

NasdaqGS:VIR

US$1.0b

NasdaqGS:ANAB

US$768.3m

NasdaqGS:RGNX

US$473.2m

NasdaqGS:MGTX

US$499.4m

가격 내역 및 성능

최근 뉴스 및 업데이트

Icosavax Files Form 15

Icosavax, Inc.(NasdaqGS:ICVX) dropped from NASDAQ Composite Index

Icosavax's Shares to be Delisted from the Nasdaq Stock Market

AstraZeneca PLC (LSE:AZN) completed the acquisition of Icosavax, Inc. (NasdaqGS:ICVX) from RA Capital Management, L.P., Qiming U.S. Healthcare Fund II, L.P., managed by Qiming Weichuang Venture Capital Management (Shanghai) Company Limited and others.

President exercised options and sold US$214k worth of stock

President exercised options to buy US$1.5m worth of stock.

Recent updates

Icosavax Files Form 15

Icosavax, Inc.(NasdaqGS:ICVX) dropped from NASDAQ Composite Index

Icosavax's Shares to be Delisted from the Nasdaq Stock Market

AstraZeneca PLC (LSE:AZN) completed the acquisition of Icosavax, Inc. (NasdaqGS:ICVX) from RA Capital Management, L.P., Qiming U.S. Healthcare Fund II, L.P., managed by Qiming Weichuang Venture Capital Management (Shanghai) Company Limited and others.

President exercised options and sold US$214k worth of stock

President exercised options to buy US$1.5m worth of stock.

Chief Medical Officer notifies of intention to sell stock

Treasurer & Chief Business Officer notifies of intention to sell stock

Price target decreased by 12% to US$21.35

AstraZeneca PLC (LSE:AZN) entered into an agreement to acquire Icosavax, Inc. (NasdaqGS:ICVX) for $760 million.

AstraZeneca PLC (LSE:AZN) entered into an agreement to acquire Icosavax, Inc. (NasdaqGS:ICVX) for $760 million.

New major risk - Revenue and earnings growth

New minor risk - Share price stability

President notifies of intention to sell stock

Chief Scientific Officer notifies of intention to sell stock

We Think Icosavax (NASDAQ:ICVX) Can Afford To Drive Business Growth

Treasurer & Chief Business Officer notifies of intention to sell stock

Price target increased by 14% to US$23.51

Icosavax, Inc. Announces Positive Topline Interim Results from Its Phase 1 Clinical Trial of Ivx-A12 Against Respiratory Syncytial Virus (Rsv) and Human Metapneumovirus (hMPV) in Older Adults

Chief Scientific Officer notifies of intention to sell stock

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 14% to US$20.69

Will Icosavax (NASDAQ:ICVX) Spend Its Cash Wisely?

President notifies of intention to sell stock

Icosavax, Inc. Appoints Jennifer Raymond as Senior Vice President, Technical Operations

President notifies of intention to sell stock

Chief Scientific Officer recently sold US$219k worth of stock

Icosavax Reports Positive Durability Data for VLP Vaccine Candidate IVX-121 Against RSV at Six-Month Timepoint

Third quarter 2022 earnings released: US$0.55 loss per share (vs US$1.30 loss in 3Q 2021)

Is Icosavax (NASDAQ:ICVX) In A Good Position To Invest In Growth?

Icosavax, Inc. Initiates Phase 1 Trial of IVX-A12 Against RSV and hMPV in Older Adults

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Icosavax GAAP EPS of -$0.57

Chief Scientific Officer notifies of intention to sell stock

Icosavax Announces Results from Ivx-411 Drug Product Investigation and Outlines Additional Corporate Milestones

Icosavax to pursue COVID bivalent vaccine in 2023 as biotech highlights near-term milestones

Icosavax, Inc. Announces Positive Topline Interim Phase 1/1b Results for VLP Vaccine Candidate IVX-121 Against RSV

Icosavax, Inc.(NasdaqGS:ICVX) dropped from Russell 2000 Growth Index

Here's Why We're Not Too Worried About Icosavax's (NASDAQ:ICVX) Cash Burn Situation

High number of new directors

Icosavax, Inc., Annual General Meeting, Jun 10, 2022

Independent Chair recently bought US$300k worth of stock

Consensus revenue estimates increase by 36%

Here's Why We're Not Too Worried About Icosavax's (NASDAQ:ICVX) Cash Burn Situation

Treasurer & Chief Business Officer notifies of intention to sell stock

Insider exercised options to buy US$1.2m worth of stock.

Chief Medical Officer exercised options to buy US$897k worth of stock.

President exercised options and sold US$91k worth of stock

High number of new and inexperienced directors

We're Hopeful That Icosavax (NASDAQ:ICVX) Will Use Its Cash Wisely

Icosavax, Inc. Announces the Initiation of A Phase 1/1B Clinical Trial of IVX-121

Independent Chairman of the Board Tadataka Yamada has left the company

Independent Chairman of the Board Tadataka Yamada has left the company

주주 수익률

가격 변동성

회사 소개

Icosavax, Inc. 기본 사항 요약

0.0x

-8.0x